Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_assertion type Assertion NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_head.
- NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_assertion description "[Biglycan has been considered a good candidate for neuromuscular disease based on direct interactions with collagen VI and alpha-dystroglycan, both of which are linked with congenital muscular dystrophy (CMD).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_provenance.
- NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_assertion evidence source_evidence_literature NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_provenance.
- NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_assertion SIO_000772 18602826 NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_provenance.
- NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_assertion wasDerivedFrom befree-20140225 NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_provenance.
- NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_assertion wasGeneratedBy ECO_0000203 NP266848.RAXlyMVf_CSD5v054QSoVu6lhVmzCC_dZ-RpZilPElak0130_provenance.